Moderna (NASDAQ:MRNA) stock has collapsed from its all-time high. However, the company is once again on the move — in a good way. The stock is up 68% over the past six months, with partnerships around artificial intelligence (AI) and positive cancer trial data garnering investor interest. Personally, though, I’m still unconvinced that these developments make MRNA stock a buy and require more data before I make a decision. For now, I remain neutral. MRNA stock has fallen significantly from its al
The mother of a man killed during a Black Lives Matter protest said Friday she was robbed of "long overdue peace" when Texas Gov.
Breaux Bridge family loses home in aftermath of storm